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Background
Primary Sjögren’s syndrome (pSS) is an autoimmune
rheumatic disease affecting the exocrine glands. Several
pSS-associated clinical and laboratory parameters may
predispose to thromboembolic risk, however clinical
data is conflicting.
My primary objective was to test whether whole blood
clot formation is abnormal in pSS using several comple-
mentary approaches: Thromboelestrography (TEG) and
Multiplate platelet mapping (MPP) for pSS patients
compared to healthy and disease (lupus-SLE) controls
and compare the size/composition of blood clots formed
ex-vivo between pSS patients and healthy controls using
a clotting chamber, which simulates the clotting process
in-vivo.
My secondary objectives were to determine if any clin-
ical/laboratory/cytokine parameters were associated with
abnormal clotting.
Methods
TEG and MPP were performed on blood samples from
12 healthy controls, 24 pSS and 11 SLE patients.
For TEG: clot formation speed, strength and lysis rate
were analysed. For MPP, platelet receptor responses to
common agonists were investigated.
12 pSS patients completed a clotting chamber
procedure.
Univariate correlation analysis was used to determine
the relationship between clotting and clinical/laboratory/
cytokine parameters.
Results
All TEG and MPP parameters were similar between
groups. Statistically significant correlations were found
for (a) ESR and clot lysis parameters (p<0.007); (b)
CD40L and clot formation/lysis rate (P<0.01).
Analysis of clot specimens from the clotting chamber
is on-going. Preliminary data indicate that several cyto-
kines are “consumed” during the clot formation.
Discussion
There was no difference in clotting and platelet recep-
tors function between pSS patients and lupus patients/
healthy controls. Interestingly, several laboratory/clinical
parameters significantly correlate with clotting/platelet
receptor function.
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